title: Luteinizing hormone-releasing hormone antagonists for urinary obstruction in prostate cancer.
abstract: Luteinizing hormone-releasing hormone (LHRH) antagonists rapidly reduce testosterone and are preferred to LHRH agonists in situations when early response is important. The lack of flare reaction, as compared to LHRH agonists, is particularly desirable as it would not aggravate the problem. A 78-year-old man presented with symptoms of urinary tract obstruction. He had a prostate-specific antigen (PSA) of 91.3 ug/L and serum creatinine 146 umol/L. He had a large pelvic mass due to histologically confirmed prostate cancer, resulting in moderate left hydronephrosis and deteriorating renal function (serum creatinine of 163 umol/L). He was started on combined degarelix and bicalutamide on the day of consultation (day 0). The hydronephrosis resolved on the repeat computerized tomography scan performed on day 10. Serum creatinine normalized to under 130 umol/L on day 18. The PSA fell to 11 ug/L on day 18, 2.8 ug/L on day 28, and 0.5 ug/L on day 53. Therefore, LHRH antagonists are particularly useful in urgent situations. It is the preferred choice in these circumstances.
authors.affiliation: Department of Radiation Oncology, Allan Blair Cancer Centre, Regina, SK.
authors.forename: Patricia
authors.initials: P
authors.lastname: Tai
authors.affiliation: Department of Radiation Oncology, Allan Blair Cancer Centre, Regina, SK.
authors.forename: Asim
authors.initials: A
authors.lastname: Amjad
authors.affiliation: Department of Radiation Oncology, Allan Blair Cancer Centre, Regina, SK.
authors.forename: Rashmi
authors.initials: R
authors.lastname: Koul
authors.affiliation: Department of Radiation Oncology, Allan Blair Cancer Centre, Regina, SK.
authors.forename: Evgeny
authors.initials: E
authors.lastname: Sadikov
authors.affiliation: Department of Radiation Oncology, Allan Blair Cancer Centre, Regina, SK.
authors.forename: Arbind
authors.initials: A
authors.lastname: Dubey